Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zydus Lifesciences Limited ( (IN:ZYDUSLIFE) ) has shared an update.
Zydus Lifesciences Limited has received approval from Health Canada for its generic Mesalamine suppositories, used in the treatment of mildly to moderately active ulcerative proctitis. This approval is expected to enhance Zydus’s market presence in Canada, where the product had annual sales of 4.86 million CAD, and it will be manufactured at their facility in Ahmedabad, India.
More about Zydus Lifesciences Limited
Zydus Lifesciences Limited is a company operating in the pharmaceutical industry, focusing on the development and manufacturing of generic drugs. The company is known for its diverse range of pharmaceutical products and services, catering to various healthcare needs.
Average Trading Volume: 45,523
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1006.1B INR
See more data about ZYDUSLIFE stock on TipRanks’ Stock Analysis page.